Lumida
/LENZ
⌘K
LENZ Therapeutics Inc

LENZ Therapeutics Inc

LENZ
$4.52USD-4.24%-0.20 today

MARKET CAP

142.0M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$5
$50

AI Summary

Stalk
TrimMedium

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

  • Moderate Buy consensus with $28.80 price target implies ~509% upside.
  • VIZZ prescriptions surged 45% month-over-month after marketing push.
  • Q2 2026 net loss of $31.9M despite VIZZ revenue growth.
Full analysis →
Insider Trades9 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 27, 2026BuyLENZDaniel R. ChevallardChief Financial Officer7,500$8.57$142.0M-91.03%+0.44%$64.3K+139.25%Trim
Mar 27, 2026BuyLENZEvert B. SchimmelpenninkPresident, CEO and Secretary28,089$8.95$142.0M-91.03%+0.44%$251.4K+57.09%Trim
Nov 17, 2025SellLENZShawn OlssonChief Commercial Officer20,000$14.09$142.0M-91.03%+0.44%$281.8K+0.00%10b5-1Trim
Nov 7, 2025BuyLENZDaniel R. ChevallardChief Financial Officer2,198$22.76$142.0M-91.03%+0.44%$50.0K+34.37%Trim
Apr 9, 2025BuyLENZShawn OlssonChief Commercial Officer1,400$2.08$142.0M-91.03%+0.44%$2.9K+2.10%Trim
Mar 7, 2025BuyLENZEvert B. SchimmelpenninkPresident, CEO and Secretary4,200$1.04$142.0M-91.03%+0.44%$4.4K+1.10%Trim
Dec 16, 2024BuyLENZShawn OlssonChief Commercial Officer3,333$2.08$142.0M-91.03%+0.44%$6.9K+5.16%Trim
Jul 22, 2024BuyLENZEvert B. SchimmelpenninkPresident, CEO and Secretary45,000$1.04$142.0M-91.03%+0.44%$46.8K+13.15%Trim
May 14, 2024BuyLENZDaniel R. ChevallardChief Financial Officer3,188$15.68$142.0M-91.03%+0.44%$50.0KTrim